Glaxo in $2.1 billion deal to develop Genmab drug

Glaxo in $2.1 billion deal to develop Genmab drug

By Malin Rising

The Wall Street Journal Europe

20 Dec 2006



COPENHAGEN — GlaxoSmithKline PLC agreed to help develop and sell an experimental blood-cancer drug from Genmab A/S, in a deal valued at as much as $2.1 billion that will strengthen Glaxo’s oncology portfolio. U.K.-based Glaxo will buy a stake of just... read more...

Tech Tags: The Wall Street Journal Europe newspaper Leading The News Index To Businesses Index To Peop

Novartis test drug shows promise in blood cancer

Novartis test drug shows promise in blood cancer

By Anita Greil

The Wall Street Journal Europe

12 Dec 2006



ZURICH—Swiss drug maker Novartis AG said an intermediatestage study showed that its experimental drug Tasigna helped many blood-cancer patients who no longer respond to treatment with its Gleevec drug. Patients in the chronic phase of chronic myeloid... read more...

Tech Tags: The Wall Street Journal Europe newspaper Corporate News Global Business Briefs

Pfizer withdraws heart drug after trial shows increased risk of death

Pfizer withdraws heart drug after trial shows increased risk of death

Sarah Boseley Health editor

The Guardian

05 Dec 2006



Trials of a drug that was expected to save millions of people from heart attacks and stroke, ushering in a new era of protective heart medicines, have been abruptly halted after it became clear that it increased the risk of patients dying. Pfizer, the... read more...

Tech Tags: The Guardian newspaper International